Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
Piccoli A, Cannata F, Strollo R, et al
National Prescribing Service (Australia)
Araszkiewicz A, Bandurska-Stankiewicz E, Borys S
This research offers further insight into this emerging safety signal, according to the study authors who noted in their Ophthalmology paper, Our novel, stratified analysis provides a more nuanced interpretation than previous pooled reviews, isolating a potential increased risk signal to observational data in the diabetes population only, a finding not corroborated by RCTs. These results are somewhat at odds with the narrative surrounding GLP-1 use and NAION risk that began in early 2024, but the researchers say they are confident in their methodology
Food and Drug Administration) Approved as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH)
US$ 24.35
US$ 22.87
US$ 22.09
